On Sept. 17, 2025, GSK announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

This includes a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States. These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States.

The $1.2 billion investment includes construction of an additional new biologics flex factory at Upper Merion, Pennsylvania to deliver potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours). Construction is planned to commence in 2026

GSK will add new AI and advanced digital technology capabilities across GSK’s existing 5 manufacturing sites in 4 States (Pennsylvania, North Carolina, Maryland, and Montana).

This announcement means GSK has committed new investments of approximately $2 billion in U.S. manufacturing over the last 12 months. In October 2024, construction began of a new $800 million facility at GSK’s Marietta, Pennsylvania site, doubling the size and capacity of the site.